These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28953659)

  • 1. Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens.
    Zhao L; Huang S; Liu J; Zhao J; Li Q; Wang HQ
    Medicine (Baltimore); 2017 Sep; 96(39):e8153. PubMed ID: 28953659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
    Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
    Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
    Zuo Y; Zhong J; Bai H; Xu B; Wang Z; Li W; Chen Y; Jin S; Wang S; Wang X; Wan R; Xu J; Fei K; Han J; Yang Z; Bao H; Shao Y; Ying J; Song Q; Duan J; Wang J
    EBioMedicine; 2022 Aug; 82():104165. PubMed ID: 35901658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
    Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
    J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma.
    Liu Y; Lu T; Yuan M; Chen R; Lu J; Wang H; Wu Z; Wang Y
    Lung Cancer; 2023 May; 179():107169. PubMed ID: 37003209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
    Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
    Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
    Zhang J; Xiang C; Han Y; Teng H; Li X; Shao J; Zhu L; Han-Zhang H; Ye J; Yu K
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):269-279. PubMed ID: 30415301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy.
    Chen M; Liu P; Yan F; Xu S; Jiang Q; Pan J; He M; Shen P
    J Transl Med; 2018 Mar; 16(1):81. PubMed ID: 29587865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.
    Garajová I; Funel N; Fiorentino M; Agostini V; Ferracin M; Negrini M; Frassineti GL; Gavelli G; Frampton AE; Biasco G; Giovannetti E
    Clin Epigenetics; 2015; 7():129. PubMed ID: 26677401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations.
    Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Dobrovic A; Moore MM; McLachlan SA
    Pathology; 2016 Jan; 48(1):17-24. PubMed ID: 27020204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.